Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCIK Immunotherapy in Renal Cell Carcinoma
NCT01240005Phase 2Unknown
- Sponsor
- Qingdao University
- Start
- Jan 2011
- Primary completion
- Dec 2012
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dendritic cell-induced killer cells in renal cell carcinoma (RCC), sponsored by Qingdao University. Primary endpoint: Overall Survival at 1 year. Status: unknown.
02
Drugs
dendritic cell-induced killer cells
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01240005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01240005.